Endothelial small-conductance and intermediate-conductance KCa channels: An update on their pharmacology and usefulness as cardiovascular targets

Heike Wulff, Ralf Köhler

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

ABSTRACT:: Most cardiovascular researchers are familiar with intermediate-conductance KCa3.1 and small-conductance KCa2.3 channels because of their contribution to endothelium-derived hyperpolarization. However, to immunologists and neuroscientists, these channels are primarily known for their role in lymphocyte activation and neuronal excitability. KCa3.1 is involved in the proliferation and migration of T cells, B cells, mast cells, macrophages, fibroblasts, and dedifferentiated vascular smooth muscle cells and is, therefore, being pursued as a potential target for use in asthma, immunosuppression, and fibroproliferative disorders. In contrast, the 3 KCa2 channels (KCa2.1, KCa2.2, and KCa2.3) contribute to the neuronal medium afterhyperpolarization and, depending on the type of neuron, are involved in determining firing rates and frequencies or in regulating bursting. KCa2 activators are accordingly being studied as potential therapeutics for ataxia and epilepsy, whereas KCa2 channel inhibitors like apamin have long been known to improve learning and memory in rodents. Given this background, we review the recent discoveries of novel KCa3.1 and KCa2.3 modulators and critically assess the potential of KCa activators for the treatment of diabetes and cardiovascular diseases by improving endothelium-derived hyperpolarizations.

Original languageEnglish (US)
Pages (from-to)102-112
Number of pages11
JournalJournal of Cardiovascular Pharmacology
Volume61
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Endothelium
Pharmacology
Apamin
Ataxia
Lymphocyte Activation
Vascular Smooth Muscle
Mast Cells
Immunosuppression
Smooth Muscle Myocytes
Rodentia
Epilepsy
B-Lymphocytes
Cardiovascular Diseases
Asthma
Fibroblasts
Macrophages
Research Personnel
Learning
T-Lymphocytes
Neurons

Keywords

  • action potential
  • afterhyperpolarizatin
  • blood pressure
  • endothelium-derived hyperpolarization
  • gating modulation
  • KCa3.1, KCa2.3
  • lymphocyte activation
  • small/intermediate-conductance calcium-activated K+ channel

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{4985205dc1754a1fb65586738267bfba,
title = "Endothelial small-conductance and intermediate-conductance KCa channels: An update on their pharmacology and usefulness as cardiovascular targets",
abstract = "ABSTRACT:: Most cardiovascular researchers are familiar with intermediate-conductance KCa3.1 and small-conductance KCa2.3 channels because of their contribution to endothelium-derived hyperpolarization. However, to immunologists and neuroscientists, these channels are primarily known for their role in lymphocyte activation and neuronal excitability. KCa3.1 is involved in the proliferation and migration of T cells, B cells, mast cells, macrophages, fibroblasts, and dedifferentiated vascular smooth muscle cells and is, therefore, being pursued as a potential target for use in asthma, immunosuppression, and fibroproliferative disorders. In contrast, the 3 KCa2 channels (KCa2.1, KCa2.2, and KCa2.3) contribute to the neuronal medium afterhyperpolarization and, depending on the type of neuron, are involved in determining firing rates and frequencies or in regulating bursting. KCa2 activators are accordingly being studied as potential therapeutics for ataxia and epilepsy, whereas KCa2 channel inhibitors like apamin have long been known to improve learning and memory in rodents. Given this background, we review the recent discoveries of novel KCa3.1 and KCa2.3 modulators and critically assess the potential of KCa activators for the treatment of diabetes and cardiovascular diseases by improving endothelium-derived hyperpolarizations.",
keywords = "action potential, afterhyperpolarizatin, blood pressure, endothelium-derived hyperpolarization, gating modulation, KCa3.1, KCa2.3, lymphocyte activation, small/intermediate-conductance calcium-activated K+ channel",
author = "Heike Wulff and Ralf K{\"o}hler",
year = "2013",
month = "2",
doi = "10.1097/FJC.0b013e318279ba20",
language = "English (US)",
volume = "61",
pages = "102--112",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Endothelial small-conductance and intermediate-conductance KCa channels

T2 - An update on their pharmacology and usefulness as cardiovascular targets

AU - Wulff, Heike

AU - Köhler, Ralf

PY - 2013/2

Y1 - 2013/2

N2 - ABSTRACT:: Most cardiovascular researchers are familiar with intermediate-conductance KCa3.1 and small-conductance KCa2.3 channels because of their contribution to endothelium-derived hyperpolarization. However, to immunologists and neuroscientists, these channels are primarily known for their role in lymphocyte activation and neuronal excitability. KCa3.1 is involved in the proliferation and migration of T cells, B cells, mast cells, macrophages, fibroblasts, and dedifferentiated vascular smooth muscle cells and is, therefore, being pursued as a potential target for use in asthma, immunosuppression, and fibroproliferative disorders. In contrast, the 3 KCa2 channels (KCa2.1, KCa2.2, and KCa2.3) contribute to the neuronal medium afterhyperpolarization and, depending on the type of neuron, are involved in determining firing rates and frequencies or in regulating bursting. KCa2 activators are accordingly being studied as potential therapeutics for ataxia and epilepsy, whereas KCa2 channel inhibitors like apamin have long been known to improve learning and memory in rodents. Given this background, we review the recent discoveries of novel KCa3.1 and KCa2.3 modulators and critically assess the potential of KCa activators for the treatment of diabetes and cardiovascular diseases by improving endothelium-derived hyperpolarizations.

AB - ABSTRACT:: Most cardiovascular researchers are familiar with intermediate-conductance KCa3.1 and small-conductance KCa2.3 channels because of their contribution to endothelium-derived hyperpolarization. However, to immunologists and neuroscientists, these channels are primarily known for their role in lymphocyte activation and neuronal excitability. KCa3.1 is involved in the proliferation and migration of T cells, B cells, mast cells, macrophages, fibroblasts, and dedifferentiated vascular smooth muscle cells and is, therefore, being pursued as a potential target for use in asthma, immunosuppression, and fibroproliferative disorders. In contrast, the 3 KCa2 channels (KCa2.1, KCa2.2, and KCa2.3) contribute to the neuronal medium afterhyperpolarization and, depending on the type of neuron, are involved in determining firing rates and frequencies or in regulating bursting. KCa2 activators are accordingly being studied as potential therapeutics for ataxia and epilepsy, whereas KCa2 channel inhibitors like apamin have long been known to improve learning and memory in rodents. Given this background, we review the recent discoveries of novel KCa3.1 and KCa2.3 modulators and critically assess the potential of KCa activators for the treatment of diabetes and cardiovascular diseases by improving endothelium-derived hyperpolarizations.

KW - action potential

KW - afterhyperpolarizatin

KW - blood pressure

KW - endothelium-derived hyperpolarization

KW - gating modulation

KW - KCa3.1, KCa2.3

KW - lymphocyte activation

KW - small/intermediate-conductance calcium-activated K+ channel

UR - http://www.scopus.com/inward/record.url?scp=84873414518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873414518&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e318279ba20

DO - 10.1097/FJC.0b013e318279ba20

M3 - Article

C2 - 23107876

AN - SCOPUS:84873414518

VL - 61

SP - 102

EP - 112

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -